ABUS
Arbutus Biopharma Corp
Halal Rating :
Last Price
$3.20
Last updated:
Market Cap
-
7D Change
-4.48%
1 Year Change
35.02%
Company Overview
Industries
Exchange
Next Earnings Date
Arbutus Biopharma Corporation is a biopharmaceutical company focused on discovering, developing, and commercializing a cure for patients suffering from chronic hepatitis B virus (HBV) infection. The company's primary revenue comes from collaboration agreements and licensing deals for its drug development technologies.
The company's pipeline includes several drug candidates targeting different aspects of HBV infection, including AB-729, AB-101, and AB-161. These products are in various stages of clinical development.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $1.34m | $22.81m | - | $29000.0 | 0.00% | 0.13% |
| June 30, 2024 | $1.73m | $23.34m | - | $34000.0 | 0.00% | 0.15% |
| March 31, 2024 | $1.53m | $20.94m | - | $44000.0 | 0.00% | 0.21% |
Company Impact
Help us evaluate Arbutus Biopharma Corp's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.